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Host defensethat can bind to incoming retroviral capsid (CA) and inhibit retroviruses in a
species-speciﬁc manner. The CA protein of HIV-1 also interacts with high afﬁnity to the host protein
cyclophilin A (CypA). This binding has been shown to positively affect some early stage of the viral life cycle
in human cells. However, the CypA/CA interaction also renders HIV-1 more susceptible to rhesus TRIM5α
(rhTRIM5α) restriction. We ﬁnd that the ability of old world monkey TRIM5α genes to restrict HIV-1 in a
CypA-dependent manner is widespread. On the other hand, we ﬁnd that simian immunodeﬁciency viruses
from tantalus monkeys (SIVagmTAN), is unlike HIV-1 in that CypA does not enhance the rhTRIM5α
restriction against the virus even though the CA of this virus, like HIV-1, does bind CypA. Mapping of the
determinants for this phenotype by swapping regions on CA between SIVagmTAN and HIV-1 showed that
when SIVagmTAN contains loops between helices 4/5 (4–5 loop) and 6/7 (6–7 loop) from HIV-1 CA, it
becomes susceptible to the CypA-enhanced rhTRIM5α restriction. Surprisingly, when SIVagmTAN contains
either loop from HIV-1 CA, it gains sensitivity to TRIM5α from species which originally have no effect on the
wild-type virus. Moreover, we ﬁnd that CypA/CA interaction occurs early after viral entry but the CypA-
enhanced restriction mostly acts on the stage after reverse transcription.
© 2008 Elsevier Inc. All rights reserved.IntroductionHosts apply many strategies to counteract viral infections. In
addition to the well known responses of the innate and adaptive
immune systems, other host proteins that are constitutively expressed
and are cell autonomous have also been shown to protect cells from
retroviral infections (Bieniasz, 2004). Among these factors, the
tripartite motif 5 isoform alpha (TRIM5α) protein can inhibit retroviral
infection in a species-speciﬁc manner (Stremlau et al., 2004). For
example, TRIM5α from rhesus macaque (rhTRIM5α) inhibits simian
immunodeﬁciency viruses from tantalus monkeys, a subspecies of
African greenmonkeys (SIVagmTAN)but not SIVs fromrhesusmacaque
(SIVmac). On the other hand, African green monkey TRIM5α (agm-
TRIM5α) inhibits SIVmac but not SIVagmTAN. Both rh and agmTRIM5α
strongly inhibit HIV-1 infection, while humanTRIM5α does not restrict
SIVmac and SIVagm, and only weakly inhibits HIV-1 (reviewed in
Newman and Johnson, 2007; Towers, 2005). Binding of TRIM5α to the
viral CA is necessary, but is not sufﬁcient for restriction of retroviruses
(Javanbakht et al., 2005; Perez-Caballero et al., 2005a).
Cyclophilin A (CypA) is a highly conserved peptidyl prolyl
isomerase that also binds to HIV-1 capsid (CA) (Franke et al., 1994;
Luban et al., 1993; Thali et al., 1994). HIV-1 directly interacts with the
CypA active site by virtue of residues in a loop between the fourthgy, Fred Hutchinson Cancer
).
l rights reserved.and ﬁfth alpha helices of CA (4–5 loop) (Bukovsky et al., 1997; Gamble
et al., 1996). This interaction can be blocked by cyclosporine A (CsA),
an immunosuppressive drug. CsA binds to the same active site of
CypA and disrupts the CypA/CA interaction which then attenuates
HIV-1 infectivity by 2–5-fold in some T cell lines (Franke and Luban,
1996; Hatziioannou et al., 2005; Sokolskaja et al., 2004). We and
others have shown that SIVagmTAN, and feline immunodeﬁciency
viruses encode CA proteins that can interact also with CypA (Diaz-
Griffero et al., 2006; Lin and Emerman, 2006; Zhang et al., 2006),
although CA of other lentiviruses such as SIVmac and equine
infectious anemia viruses do not interact with CypA (Braaten et al.,
1996b; Lin and Emerman, 2006). Therefore, CypA/CA interaction is a
common, but not universal phenotype among lentiviruses.
Interestingly, the positive effect of CypA/CA interaction on HIV-1
replication in human cells is reversed in some old world monkey cells.
This is because the interaction of CypA with HIV-1 CA renders HIV-1
more susceptible to the restriction from rh and agmTRIM5α proteins
(Berthoux et al., 2005; Keckesova et al., 2006; Sokolskaja et al., 2006;
Stremlau et al., 2006b). Therefore, the ability of HIV-1 CA to bind CypA
enhances virus replication in many human cells, but negatively affects
its ability to infect old world primate cells.
In this report, we identiﬁed the regions on CA that render HIV-1
more susceptible to the TRIM5α restriction when bound by CypA.
First, we show CypA has no effect on enhancing the restriction of
another CypA-binding virus, SIVagmTAN. By generating chimeric
SIVagmTAN containing fragments from HIV-1 CA, we mapped the
determinants on HIV-1 CA that make HIV-1 more sensitive to TRIM5α
Fig. 1. Cyclophilin A/capsid interaction renders HIV-1, but not SIVagmTAN, more
susceptible to rh, agm, and baboonTRIM5α restriction. CRFK and CRFK cells expressing
rh, agm, and baboonTRIM5α were infected with wild-type HIV-1 (A), HIV-1 G89V (B),
and SIVagmTAN (C) in the presence (CsA+, ﬁlled boxes) or absence (CsA−, open boxes) of
CsA. The infected cells were analyzed by luminometer and the infectivity is presented as
relative luciferase units (RLU, on a log scale).
336 T.-Y. Lin, M. Emerman / Virology 379 (2008) 335–341after CypA binding to two regions located at the 4–5 loop in CA and
another loop between the sixth and seventh helices (6–7 loop). These
two regions of HIV-1 CA are both necessary to transfer the CypA-
dependent TRIM5α sensitivity to SIVagmTAN. Moreover, we found
that these regions determine viral sensitivity to TRIM5αs even in the
absence of CypA. Consistent with previous reports (Keckesova et al.,
2006; Stremlau et al., 2006b), our data show that TRIM5α restriction
of HIV-1 is composed of both CypA-dependent and CypA-independent
components. Here we show that the CypA-enhanced TRIM5α
restriction effect occurs early after viral entry and persists for 4–8 h
after infection, and appears to occurmostly after reverse transcription.
These results identify the viral determinants that render the HIV-1 CA
susceptible to a CypA-dependent TRIM5α restriction.
Results
Old world monkey TRIM5α restriction against HIV-1 has both
CypA-dependent and CypA-independent components
The CypA-dependent TRIM5α restriction against HIV-1 was
observed in rhesus macaque and African green monkey cells
(Berthoux et al., 2005; Keckesova et al., 2006; Stremlau et al.,
2006b). These reports suggest that the CypA/CA interaction renders
HIV-1 more susceptible to the restriction by TRIM5αs from old world
primates. BaboonTRIM5α also potently inhibits HIV-1 infection
(Kaiser et al., 2007). Thus, we examined the CypA-dependence of all
three TRIM5α restriction factors in parallel in the same cell type. CRFK
cells expressing rh, agm, and baboonTRIM5α were generated and
infected with VSV-G pseudo-typed wild-type HIV-1 (Fig. 1). CsA was
added upon infection to validate the dependence of TRIM5α
restriction on CypA/CA interaction. Infections were done with viruses
encoding luciferase gene as a reporter, and the relative luminescence
unit (RLU) after infection was used as an indicator for infection. The
luciferase reporter gives us a longer dynamic assay range than the GFP
reporter system, therefore the low level of infectivity under TRIM5α
restriction can still be within the linear range of the assay.
Consistentwith previous reports, CypA/CA interaction rendersHIV-
1 more susceptible to rhTRIM5α restriction (Berthoux et al., 2005).
That is, addition of CsA to block CypA/CA interaction rescues HIV-1
infection from rhTRIM5α restriction by at least 10-fold (t-test, p
valueb0.05). As a control we also used HIV-1 G89V, amutant that does
not bind CypA (Franke et al., 1994). Consistent with previous reports
that used other readouts for infection (Berthouxet al., 2005; Keckesova
et al., 2006; Sokolskaja et al., 2006; Stremlau et al., 2006b), HIV-1 G89V
is susceptible to the rhTRIM5α inhibition, but the level of infectivity is
not affected by the addition of CsA (Fig. 1A). On the other hand, adding
CsA to block CypA/CA interaction can rescue HIV-1 infection from agm
and baboonTRIM5α by about 4-fold (t-test, pb0.05). This suggests that
CypA-dependent restriction of TRIM5α is widespread among the old
world primate TRIM5α genes.
The data in Fig. 1 also shows that disruption of CypA/CA interaction
with CsA is not able to fully rescue HIV-1 infectivity in CRFK cells.
Although the disruption of CypA/CA interaction by CsA rescues HIV-1
infection by10-fold, it is still 100-fold lower than that in CRFK cells that
express no TRIM5α (Fig. 1B). This ﬁnding is consistent with previous
reports (Keckesova et al., 2006; Stremlau et al., 2006b). The same
phenotype is also observed in agm and baboonTRIM5α restriction
against HIV-1 infection (Fig. 1A). Therefore, these data suggest that rh,
agm, and baboonTRIM5α are potent inhibitors against HIV-1 infection,
but that the restriction consists of both CypA-independent and CypA-
dependent stages.
TRIM5α restriction against SIVagmTAN is not CypA-dependent
SIVagmTAN is susceptible to rhTRIM5α, slightly inhibited by
agmTRIM5α, and resistant to baboonTRIM5α restriction (Fig. 1C).Because SIVagmTAN, like HIV-1, is able to bind CypA (Lin and
Emerman, 2006; Zhang et al., 2006) and is susceptible to rhTRIM5α
restriction, we examined whether or not the CypA/CA interaction in
SIVagmTAN also renders the virus more susceptible to TRIM5α
restriction. We found that, unlike HIV-1, the restriction of
SIVagmTAN by rhTRIM5α is not affected by CsA (Fig. 1C). In
rhTRIM5α-expressing cells, the infectivity of SIVagmTAN only
increases by 2-fold in the presence of CsA (p valueN0.05, Fig. 1C).
We veriﬁed that CsA does block CypA/CA interaction in SIVagmTAN
by examining the infection of the virus in TRIMCyp-expressing CRFK
cells with or without CypA (Lin and Emerman, 2006 and data not
Fig. 2. HIV-1 susceptibility to the CypA-enhanced TRIM5α restriction is determined
by the loop between the 4th and 5th helices and the loop between 6th and 7th
helices on viral capsid. (A) Diagram of chimeric SIVagm-45L, SIVagm-67L, and
SIVagm-45/67L in which the loop between the 4th and 5th helices or the loop
between 6th and 7th helices or both loops on SIVagmTAN capsid were replaced by
those from HIV-1. (B) CRFK and CRFK cells expressing rhTRIM5α were infected with
wild-type HIV-1, SIVagmTAN, and recombinant SIVagm in the presence or absence of
CsA. Infected cells were harvested and analyzed by luminometer, and the infectivity
is presented as relative luciferase unit (RLU, on a log scale). (C) The normalization of
infection from (B). The open boxes were obtained by dividing the RLU from the
yellow boxes of each infection in panel B by the blue boxes in panel B times 100, and
the ﬁlled boxes were obtained by dividing the RLU from the green boxes of each
infection in panel B by the black boxes in panel B times 100.
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not universally dependent on CypA, but rather is virus-speciﬁc. The
ability of viral CA to interact with CypA does not necessarily result
in the CypA-dependent restriction.
The CypA-dependent TRIM5α restriction is determined by loops between
the 4th/5th and the 6th/7th helices on viral capsid
Since HIV-1 and SIVagmTAN both bind CypA but their suscept-
ibilities to CypA-dependent rhTRIM5α restriction are different, we
speculated that viral capsid determines this phenotypic variation.
Hatziioannou et al. reported that the 4–5 loop and another loop
between the 6th and 7th helices (6–7 loop) on HIV-1 CA modulate
HIV-1 tropism in different primate cells (Hatziioannou et al., 2004).
Therefore, we investigated if these loops are determinants for the
CypA-dependent TRIM5α restriction with chimeric SIVagmTAN
where the 4–5 loop, 6–7 loop, and both 4–5 and 6–7 loops were
replaced by those parallel ones from HIV-1 CA (Fig. 2). Accordingly,
these chimeric SIVagmTAN were named SIVagm-45L, SIVagm-67L,
and SIVagm-45/67L (Fig. 2). These recombinant SIVagm were
pseudotyped with VSV-G and used to infect cells expressing
rhTRIM5α in the presence or absence of CsA (Fig. 2). The amount of
virus that gives about 107 RLU was used to infect CRFK cells (blue
boxes, Fig. 2). Similar to the CypA effect for HIV-1 replication in human
cells, the infections of wild-type HIV-1, SIVagm-45L, SIVagm-67L, and
SIVagm-45/67L were slightly affected in CRFK cells in the presence of
CsA (compare blue boxes with black boxes, Fig. 2).
We ﬁnd that each of the chimeric SIVagm viruses (Fig. 2) is more
susceptible to rhTRIM5α inhibition thanwild-type SIVagmTAN (Fig. 2,
yellow boxes compared to black boxes). Because of this observation
and because there are different viruses in the experiment, we set the
viral infectivity in CRFK cells (without a primate TRIM5α) as 100% and
normalized the infectivity in TRIM5α-expressing cells based on it.
That is, the infectivity in rhTRIM5α/CsA− (yellow boxes, Fig. 2A) was
normalized to the infectivity in CRFK/CsA− (blue boxes, Fig. 2) to
obtain the open boxes in Fig. 2C, and the infectivity in rhTRIM5α/CsA+
(green boxes, Fig. 2) was normalized to the infectivity in CRFK/CsA+
(black boxes, Fig. 2) to obtain the ﬁlled boxes in Fig. 2C so that the
relative effects of CsA on the TRIM5α inhibition can be directly
compared.
We ﬁnd that the level of the CypA-dependent rhTRIM5α restriction
against chimeric SIVagm-45L is similar to that of SIVagmTAN, not HIV-
1 (ﬁlled boxes, Fig. 2C). This suggests that the 4–5 loop, which is
important for the CypA/CA interaction, is not sufﬁcient for the viral
susceptibility to the CypA-dependent TRIM5α restriction.
Likewise, the level of the CypA-dependent rhTRIM5α restriction
against chimeric SIVagm-67L remains similar to that of SIVagmTAN,
not HIV-1 (ﬁlled boxes, Fig. 2). Remarkably, however, the chimeric
SIVagm-45/67L (with both the 4–5 and6–7 loops exchanged fromHIV-
1, Fig. 2) not only becamemore sensitive toTRIM5α but also gained the
susceptibility to the CypA-dependent restriction (Fig. 2C). These data
suggest that the 4–5 and 6–7 loops form a domain that confers
cyclophilin-dependent viral susceptibility to TRIM5α restriction.
Loops between the 4th/5th and the 6th/7th helices on viral capsid affect
viral susceptibility to TRIM5α restriction
Wenoticed that chimeric SIVagm-45L, SIVagm-67L, and SIVagm-45/
67L are more sensitive than wild-type SIVagmTAN to rhTRIM5α
restriction (Fig. 2C; notice the open boxes of each SIVagm chimeric
virus compared to SIVagmWT). To examinewhether these recombinant
viruses are generally more sensitive to TRIM5αs, SIVagm-45L, SIVagm-
67L and SIVagm-45/67L were used to infect CRFK and CRFK cells which
express agm or baboonTRIM5α (Fig. 3). When the 4–5 loop on SIVagm
CAwas replaced by that from HIV-1, the susceptibility of SIVagm-45L to
agmTRIM5α is similar to that of wild-type SIVagm (Fig. 3, compare theopen boxes). However, when 6–7 or both 4–5 and 6–7 loops on SIVagm
CA were replaced, the chimeric SIVagm viruses become more suscep-
tible than the wild-type virus to agmTRIM5α restriction (open boxes,
Fig. 4. Cyclophilin A-enhanced TRIM5α restriction occurs in early viral life cycle. Time
course experiment of withdrawing CsA from wild-type HIV-1 (A) and SIVagm-45/67L
(B) infected rhesus macaque (SMAGI) cells. Viruses were spinoculated at 8 °C for 20 min
and transferred to a 37 °C incubator to synchronize viral entry. The presence (CsA+) and
absence (CsA−) of cyclosporin A (CsA) throughout the experiment was used as controls.
For the withdrawal groups, CsA was added to cells when transferring plates to a 37 °C
incubator, and the time was set as time 0. CsA was then withdrawn at 10 min, 30 min,
1 h, 2 h, 4 h, 8 h, 12 h, or 24 h after time 0. Infected cells were harvested after 48 h and
analyzed by luminometer. The infectivity is presented as RLU (on a log scale).
Fig. 3. Viral susceptibility toTRIM5α restriction is affected by loops between the 4th/5th
and 6th/7th helices on capsid. Infection of wild-type SIVagmTAN, chimeric SIVagm-45L,
SIVagm-67L, and SIVagm-45/67L in agmTRIM5α (A) and baboonTRIM5α (B) -
expressing cells. Infected cells were harvested and analyzed by luminometer, and the
infectivity is presented as relative luciferase unit (RLU, on a log scale).
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SIVagm-67L are resistant to the inhibition from baboonTRIM5α, but
recombinant SIVagmwith the4–5orboth4–5and6–7 loops fromHIV-1
CA gain susceptibility to baboonTRIM5α restriction (open boxes, Fig. 3).
Thus, both CA loops from HIV-1 independently confer different
sensitivities to TRIM5α from different old world monkeys.
We also examined the dependence of CypA on these Trim5α
restrictions. The CypA/CA interaction does not enhance agm and
baboonTRIM5α restriction against wild-type SIVagmTAN, SIVagm-
45L, and SIVagm-67L (Fig. 3, hatched boxes). However, when both the
4–5 and 6–7 loops on SIVagmTAN (SIVagm-45/67L) were replaced by
those from HIV-1 CA, the CypA/CA interaction sensitizes this mutant
virus to the CypA-dependent TRIM5α restriction. These results
indicate that while the 4–5 loop and the 6–7 loop can each alter the
species-speciﬁc susceptibility of viruses to TRIM5αs from different
species, both loops are necessary for the viral susceptibility to the
CypA-dependent TRIM5α restriction for all three of the TRIM5α genes
tested (Figs. 2 and 3). Therefore, the phenotype of HIV-1 that encodes a
capsid which becomes more susceptible to TRIM5α proteins after
binding to CypA can be transferred to another retrovirus by trans-
ferring parts of the CA protein in addition to transferring susceptibility
in general to TRIM5α from old world monkeys.
The CypA-dependent TRIM5α restriction occurs early after viral entry,
but is mostly post-reverse transcription
In human cells, CypA is important for the early step of HIV-1
replication (Braaten et al., 1996a). To determine how early the CypA-dependent TRIM5α restriction affects HIV-1 replication, we con-
ducted a time course experiment by withdrawing CsA from infected
rhesus cells. CsA was present when adding HIV-1 to cells and was
removed at different time points (Fig. 4). When CsA was withdrawn
10 min or 30 min after infection, the infectivity of HIV-1 is similar to
the infectivity in cells without the presence of CsA. This indicates that
30 min of CsA treatment is not enough to overcome the CypA-
dependent rhTRIM5α restriction. When CsA was removed 1 h after
infection, the infectivity of HIV-1 increases by 2-fold when compared
to the infectivity in cells without the addition of CsA (p valueb0.05,
Fig. 4). The level of HIV-1 infectivity gradually increases with the time
of CsA treatment. When CsAwas withdrawn at 8 h after infection, the
infectivity of HIV-1 reached the level where CsA was present
throughout the experiment. This data suggests that the CypA-
dependent TRIM5α restriction against HIV-1 infection occurs early
and persists for at least at the ﬁrst 8 h of replication cycle.
We also examined the time course of rhTRIM5α restriction against
SIVagm-45/67L by withdrawing CsA at different time points after
infection (Fig. 4). The time course of the CypA-dependent rhTRIM5α
restriction against SIVagm-45/67L shows a similar pattern as that of
HIV-1, although the kinetics of CsA-withdrawn effect in SIVagm-45/
67L is faster than that in HIV-1. The presence of CsA in the ﬁrst 30 min
already starts to rescue SIVagm-45/67L from the CypA-dependent
rhTRIM5α restriction. The level of SIVagm-45/67L infectivity also
gradually increases with the time when CsA was removed. Taken
together, the data suggest that CypA-dependent TRIM5α restriction
against chimeric SIVagm-45/67L occurs early after viral entry, and
CypA/CA interaction no longer enhances rhTRIM5α 2 h after viral
entry.
It has been proposed that TRIM5α restriction against retroviral
infection can be divided to the inhibition before reverse transcrip-
tion and the inhibition after reverse transcription (Anderson et al.,
2006; Wu et al., 2006). To examine which phase of the HIV-1 life
cycle is affected by the CypA-dependent TRIM5α restriction, we
used a real-time PCR assay to study the late reverse transcription
Fig. 5. Cyclophilin A-enhanced TRIM5α restriction impacts viral replication in the
stage after reverse transcription. SMAGI cells were infected with wild-type HIV-1 in
the presence (CsA+) or absence (CsA−) of cyclosporine A. Infected cells were
harvested 24 h after infection and the viral DNA were collected for the detection of
late reverse transcription products (late RT) and 2-LTR circles (2-LTR) by real-time
PCR. The overall infectivity was analyzed by luminometer 48 h after infection and
presented as RLU (on a log scale).
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infection of rhesus cells (endogenous rhTRIM5α) with or without
CsA (Fig. 5). The infectivity of HIV-1 is inhibited by rhTRIM5α, and
the addition of CsA upon infection can rescue HIV-1 from the
restriction by 10-fold. However, when we examined the late RT
harvested from HIV-1 infected rhTRIM5α-expressing cells, we found
that the CsA addition brings up the RT product level by only about
2-fold. On the other hand, the addition of CsA increases about 5-fold
more nuclear 2-LTR circles when compared to the group without
CsA treatment. Similar results were observed in CRFK cells that
exogenously express rhTRIM5α (data not shown). These results
suggest that the CypA-dependent rhTRIM5α restriction can impact
HIV-1 replication at reverse transcription but mostly affects the
stages after reverse transcription.Discussion
The capsid protein from HIV-1 and SIVagmTAN can both interact
with CypA (Lin and Emerman, 2006; Zhang et al., 2006). However, in
this report we show that SIVagmTAN, unlike HIV-1, is restricted by
rhTRIM5α independent of CypA/CA interaction. We used this
difference to map the viral determinant for this phenotype, and
showed that two loops on HIV-1 capsid, one between the 4th and 5th
helices and the other between the 6th and 7th helices, are responsible
for the HIV-1 susceptibility to the CypA-dependent TRIM5α restric-
tion. Interestingly, just by replacing one of the two loops from HIV-1,
SIVagmTAN gains susceptibility to the TRIM5αs that originally had
little effect on the wild-type virus. Moreover, we report here that the
CypA-dependent TRIM5α restriction against lentiviral infection
occurs early and affects replication mostly after reverse transcription.
It has been reported that in the absence of the vif gene, CypA is
incorporated into SIVagm from human cells and can inhibit virus
infection in the next round of infection (Takeuchi et al., 2007).
Although CypA does not enhance TRIM5α restriction against wild-
type SIVagmTAN in target cells, it is possible that the CypA or TRIM5α
from producer cells could confound our ﬁndings. However, since our
virus encodes a functional vif gene, it is not likely that our results can
be explained by CypA or TRIM5α proteins from the producer cells.
Rather, CypA and TRIM5α in the target cells are more likely to have an
effect on the SIVagmTAN mutants in which portions of the HIV-1 CA
have been substituted. These results reﬂect the ﬁndings that CypA is
more important in target cells than in producer cells for HIV-1
replication (Hatziioannou et al., 2005; Sokolskaja et al., 2004).
In some human cells, the CypA/CA interaction has been shown to
assist HIV-1 replication (Franke and Luban, 1996; Hatziioannou et al.,
2005; Sokolskaja et al., 2004; Thali et al., 1994). It has been
hypothesized that humans encode an unknown factor that cannegatively affect HIV-1 replication, and CypA binding to HIV-1 CA
can protect HIV-1 from this unknown factor (Sokolskaja et al., 2006;
Towers et al., 2003). On the other hand, CypA functions negatively for
HIV-1 replication in old world monkey cells because CypA/CA
interaction sensitizes HIV-1 to the restriction from old world monkey
TRIM5α proteins (Berthoux et al., 2005; Keckesova et al., 2006;
Stremlau et al., 2006b). These ﬁndings complicate the complex puzzle
of the CypA role in HIV-1 life cycle. A mechanism has been proposed
that CypA binding to HIV-1 CA induces the conformational change of
viral core and renders HIV-1 CA more readily recognizable by the C-
terminal B30.2 domain of TRIM5α (Berthoux et al., 2005; Keckesova
et al., 2006). Our data suggests that if the conformation theory is true,
then the domain consisting of both the 4–5 and 6–7 loops on HIV-1 CA
is the key region that determines whether or not a TRIM5α restriction
can be enhanced by CypA/CA interaction. Because the 4–5 and 6–7
loops are the regions on viral CA that are exposed to the intracellular
environment, they encounter many intracellular factors, and the
conformational change of this area can affect the afﬁnity of viral CA to
these factors. After the conformational change induced by CypA
binding, the domain formed by the 4–5 and 6–7 loops could become
more accessible to TRIM5α.
Nonetheless, the CypA-induced conformational change of viral
core only explains part of the TRIM5α restriction. If a virus does not
bind CypA (e.g. G89V HIV-1 or SIVmac), this virus is still susceptible to
the TRIM5α restriction in a CypA-independent manner (Fig. 1 and
Stremlau et al., 2006b). This suggests that if the TRIM5α restriction
contains both CypA-independent and CypA-dependent components,
then the CypA-dependent stage might inhibit viruses after the capsid
conformation has been changed by CypA binding, while the CypA-
independent stage might inhibit susceptible viruses irregardless of
CypA-binding status.
Moreover, our results of the recombinant SIVagm containing the
4–5 or 6–7 loop from HIV-1 CA showed that the degree of viral
sensitivity to TRIM5α does not necessarily correlate with the CypA-
dependent TRIM5α restriction (Figs. 2 and 3). The CypA-enhancement
of TRIM5α restriction is only detected in viruses that contain both the
4–5 and 6–7 loops from HIV-1 CA. These data suggest that the domain
formed by the 4–5 and 6–7 loops is the region directly recognized by
TRIM5α. Replacing only one loop can already affect the CypA-
independent TRIM5α restriction, but it requires two loops to change
the CypA-dependency of TRIM5α restriction.
Interestingly, transferring this domain from HIV-1 CA to another
retrovirus transfers not only the susceptibility to the CypA-dependent
TRIM5α restriction but also the sensitivity in general to TRIM5α from
old world monkeys (Figs. 2 and 3). These further conﬁrm that HIV-1
encodes a CA that is susceptible to both CypA-independent and CypA-
dependent TRIM5α restriction. Hatziioannou et al. also reported
similar observations in that when they replaced the 4–5, 6–7 loops
and the β-turn on HIV-1 capsid with those from SIVmac, these
exposed variable regions on capsid modulate HIV-1 tropism which is
mediated by host intracellular restriction factors such as TRIM5α
(Hatziioannou et al., 2004). Furthermore, it has been shown that
swapping only the 4–5 loop between two closely related HIV-2 and
SIVmac can transfer the viral susceptibility and insensitivity to
TRIM5α (Ylinen et al., 2005). Our results presented here show that,
in more distantly related viruses (HIV-1 and SIVagm), the 6–7 loop is
also independently involved in the transfer of TRIM5α susceptibility.
In addition to these regions on CA, the ridge formed by helices 3
and 6 on CA has also been reported to determine viral susceptible to
the TRIM5α restriction (Owens et al., 2004). It has been shown that
helix 6 interacts with the CypA-binding loop through hydrogen-
bonding (Gitti et al., 1996; Tang et al., 2002). It is possible that CypA
interacts with the 4–5 loop, inducing the conformational change, and
subsequently affecting areas surrounding the 4–5 loop, such as the 6–
7 loop. Therefore, retroviral CA determines the species-speciﬁc
tropism after entry, and the 4–5 and 6–7 loops are probably the
340 T.-Y. Lin, M. Emerman / Virology 379 (2008) 335–341target domain recognized by host intracellular factors, such as CypA
and TRIM5α, that are able to affect the infection.
It has been shown that TRIM5α can only target the incoming viral
core, not monomeric capsid protein, for restriction (Dodding et al.,
2005; Sebastian and Luban, 2005; Stremlau et al., 2006a). Because
viral core quickly begins uncoating once in a cell, TRIM5α rapidly loses
the target ligand of the viral core (multimeric capsids). Therefore, in
order to enhance the TRIM5α restriction, CypA has to interact with the
incoming core before it undergoes uncoating. However, the persis-
tence of 8 h of CypA-enhancement for TRIM5α function suggests that
the CypA-dependent TRIM5α inhibition acts on a later event after
reverse transcription. This hypothesis is supported by the real-time
PCR data that the CypA-dependent restriction can inhibit reverse
transcription, but it mostly restricts the step after the completion of
reverse transcription (Fig. 5).
In conclusion, we report here that HIV-1 encodes a CA that renders
the virus more susceptible to old world monkey TRIM5α restriction
when bound by CypA, and further determined the regions on CA that
are responsible for the phenotype. The fact that HIV-1 is unusual in its
susceptibility to the CypA-dependent TRIM5α restriction suggests
that this may be an important component of its host-species
restriction, or its adaptation to hominoids.
Materials and methods
Cells
293 T cells were used for generation of vesicular stomatitis virus G
protein (VSV-G) pseudotyped HIV-1, SIVagmTAN, and SIVagm-45L,
SIVagm-67L, and SIVagm-45/67L. CRFK (Crandall Feline Kidney) cells
expressing rhTRIM5α, agmTRIM5α, and baboonTRIM5α proteins
were generated as described previously (Kaiser et al., 2007). SMAGI
(rhesus) cells were a kind gift of Julie Overbaugh (Chackerian et al.,
1995) (Fred Hutchinson Cancer Research Center, Seattle, USA). All cells
were cultured in Dulbecco's modiﬁed Eagle medium with 10% fetal
bovine serum.
Construction of chimeric viruses
HIV-LaiΔEnv-Luc was generated from wild-type HIV-Lai strain
previously in the laboratory (Yamashita and Emerman, 2004). The
plasmid of pSIVagmTANΔEnvΔRev-Luc, which wasmodiﬁed fromwild-
type pSIVagmTan-1 (Cat # 3444, NIH AIDS Research and Reference
Reagent Program) (Soares et al., 1997), was a gift of Nathaniel Landau
(New York University, New York, USA). For easier manipulation, a
pBluescript-SIVagmApaI-2965 containing the fragment between Apa I
(850 bp upstream of the 5′ LTR) and the 2965th bp of pSIVagmTAN-
ΔEnvΔRev-Lucwas constructed. To replace the CypA-binding loop (4–
5 loop) on SIVagmTANwith that from HIV-1, three separate PCRs were
applied. The ﬁrst PCR ampliﬁed the 5′ end sequence of the 4–5 loop,
from 686 bp to 1573 bp of pSIVagmΔEnvΔRev-Luc, with a Kas I
restriction site (at the 708th bp) and the HIV-1–5 loop sequence
ﬂanking at the 3′ end. Primer sets used for the ﬁrst PCR are 5′-
AGGCTGAGAAATCTCCAGCAGTGGCGCCCG-3′ (forward) and 5′-
TGGTGCAATAGGCCCTGCATGCACTGGGTGTGTTATATCCCACTGG-3′
(reverse). The second PCR ampliﬁed the 3′ end sequence of the 4–5
loop, from 1601 bp to 2965 bp of pSIVagmΔEnvΔRev-Luc, with the HIV-
1–5 loop sequence ﬂanking at the 5′ end and a SnaB I restriction site
(at the 1814th bp). Primer sets used for the second PCR are 5′-
CCAGTGCATGCAGGGCCTATTGCACCAGGGCAGCTAAGGGACCC-3′ (for-
ward) and 5′-TCCACTGTGTTTTGTCTTTTTTCCGGATAC-3′ (reverse).
The third PCR used the PCR products from the ﬁrst and second
reactions as the template and forward primer from the ﬁrst and
the reverse primer from the second reaction to combine these two
fragments. The PCR products were digested with the Kas I and
SnaB I restriction enzymes and inserted to the pBluescript-SIVagmApaI-2965, which was subsequently digested with Apa I
and Sna BI and transferred to pSIVagmΔEnvΔRev-Luc to generate
pSIVagmΔEnvΔRev-Luc-45L.
Same three-step PCR and cloning strategy was applied to replace
the loop between the 6th and 7th helices (6–7 loop) on SIVagmTAN
with that from HIV-1. Primer sets used for the ﬁrst PCR are 5′-
AGGCTGAGAAATCTCCAGCAGTGGCGCCCG-3′ (forward) and 5′-
TGGGATAGGTGGATTATTAAAAGTCCACTCTATTTGCTCAGC-3′ (reverse);
primers for the second PCR are 5′-AATAATCCACCTATCCCAGTAGGACG-
TATCTACAGAGGATGGG-3′ (forward) and 5′-TCCACTGTGTTTTGTCTT-
TTTTCCGGATAC-3′ (reverse). The ﬁrst PCR ampliﬁed the 5′ end
sequence of the 6–7 loop, from 686 bp to 1678 bp of pSIVagmΔE-
ΔRev-Luc, with the HIV-1–7 loop sequence ﬂanking at the 3′ end. The
second PCR ampliﬁed the 3′ end sequence of the 6–7 loop, from
1700 bp to 2965 bp of pSIVagmΔEnvΔRev-Luc, with the HIV-1–7 loop
sequence ﬂanking at the 5′ end. The third PCR used the PCR products
from the ﬁrst and second reactions as the template and forward
primer from the ﬁrst and the reverse primer from the second reaction
to combine these two fragments. The PCR products were cloned to
pBluescript-SIVagmApaI-2965 ﬁrst (after Kas I and Sna BI digestion)
and transferred to pSIVagmΔEnvΔRev-Luc (after Apa I and Sna BI
digestion) to generate pSIVagmΔEnvΔRev-Luc-67L.
To construct the pSIVagmΔEnvΔRev-Luc-45/67L, pSIVagmΔE-
ΔRev-Luc-45L was digested with Apa I and Ppu MI and swapped
with pSIVagmΔEnvΔRev-Luc-67L. Due to the length of the pSIVagm-
ΔEnvΔRev-Luc plasmid, all three constructed SIVagmTAN plasmids
were transformed into Stbl3 competent cells (Invitrogen) and grown
under the instruction of the manufacturer's protocol.
Generation of VSV-G pseudotyped viruses
2.5×105 cells/ml of 293 T cells were plated in a 6-well plate (2 ml/
well) 16 h prior to transfection. The VSV-G pseudotyped HIV-1 (WT),
SIVagmTAN (WT), SIVagm-45L, SIVagm-67L, and SIVagm-45/67L were
generated as described previously (Lin and Emerman, 2006). Culture
media were collected on 48 and 72 h after transfection, and were
passed through a 0.2 μm ﬁlter (Nalgene) to remove cell debris. All
harvested viruses were ultra-centrifuged in an SW28 rotor at
23,000 rpm at 4 °C for 1.5 h for concentrating viruses by 100-fold.
All viruses were allotted in 1.5 ml micro-tubes and frozen at −80 °C
until use. The viral titer was tested by infecting CRFK cells with
different volumes of the viral stocks, and the amount of virus
generating 106 relative luminance units (RLU) was determined.
Infection and TRIM5α restriction assay
CRFK or CRFK cells expressing TRIM5α proteins or SMAGI cells
were plated 16 h before infection at a density of 1×105 cells/ml on a
96-well (0.1 ml/well) plate. A volume of VSV-G pseudotyped viruses
that had been previously titered on CRFK cells to give 106 RLU after
infection were used. Infections were done in the presence of 20 μg/ml
of DEAE-Dextran in the presence or absence of 3 μM CsA and
spinoculated at 1200 relative centrifugal force (rcr) at room
temperature for 20 min (O'Doherty, Swiggard, and Malim, 2000).
The infected cells were placed at 37 °C incubator for 48 h until the
analysis of the infectivity. After aspirating culture media, 100 μl of 1×
lysis buffer (Promega) were added to the infected cells and incubated
at room temperature for 5 min. 100 μl of BrightGlo (Promega) reagent
were then added to the lysed cells. The plate was placed at room
temperature for 1 min and the relative luminance units (RLU) were
measured with luminometer to determine the infectivity. The CsA-
withdrawing experiment was conducted by following a protocol
modiﬁed from a previously published report (Perez- Caballero et al.,
2005b). The spinoculation stepwas performed at 8 °C for 20min. After
spinoculation, the inoculants were removed, and cells were washed
with cold media for three times. Fresh media, with or without 3 μM of
341T.-Y. Lin, M. Emerman / Virology 379 (2008) 335–341CsA, were added to cells after washing. Cells were then placed at 37 °C
incubator for 48 h. Media containing CsA were removed at 10 min,
30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h after placing plates at 37 °C
incubator. Those cells were washed with media for three times, and
fresh media were added to wells to maintain the growth of cells. The
viral infectivity was analyzed as described above.
Real-time PCR
SMAGI cells were plated 16 h before infection at a density of
2.5×105 cells/ml on a 6-well plate (2 ml/well). The pre-titered VSV-G
pseudotypedHIV-1 stockswere added to target cells in the presence of
20 μg/ml DEAE/Dextran, and spinoculated at 1200 relative centrifugal
force (rcf) at room temperature for 20 min. The plates were placed at a
37 °C incubator until the analysis of the late reverse transcription
products, 2-LTR circles, or the infectivity. One day after inoculating
viruses, cells were trypsinized and viral DNA was extracted with
DNeasy Blood and Tissue Kit (Qiagen). Two days after inoculating
viruses, viral infectivity was analyzed with assays described above.
Viral late reverse transcription products and 2-LTR circles were
measured by using real-time PCR with protocols described previously
(Butler, Hansen, and Bushman, 2001; Yamashita and Emerman, 2004).
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